Japan’s MHLF approves Padcev with Keytruda for first-line treatment of radically unresectable urothelial carcinoma: Tokyo Wednesday, September 25, 2024, 11:00 Hrs [IST] Astellas ...
Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...
Summit Therapeutics and Akeso published results for the Phase III HARMONi-2 trial, which tested ivonescimab, a bispecific ...
ThePrint on MSN4d
This experimental lung cancer drug outperforms blockbuster medicine Keytruda. But there’s a catchIn head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by ...
Summit Therapeutics acquired rights to ivonescimab outside of China and Australia. With Keytruda sales up around $25 billion ...
Zacks Small Cap Research on MSN10h
AEMD: Positive Takeaways from Life Science Investor Forum PresentationAEMD READ THE FULL AEMD RESEARCH REPORT AEMD basket oncology trial, patient enrollment process We participated in a ...
Better-than-expected trial data means Summit's bispecific antibody could replace the blockbuster Keytruda as a standard of ...
Summit's ivonescimab outperforms Keytruda in lung cancer trial, positioning the company to capture a significant market share ...
Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...
Akeso and Summit Therapeutics' ivonescimab showed strong efficacy against Merck's Keytruda in a phase 3 trial in China. The ...
BT-001 is a multifunctional oncolytic virus encoding for an anti-CTLA4 antibody and the cytokine GM-CSF ... BT-001 induced tumor shrinkage in 2 of 6 injected lesions.In combination with KEYTRUDA® ...
The European Society for Medical Oncology’s annual meeting this week featured the hottest emergent areas of cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback